AI’s Role in Reducing Healthcare Waste and Cost

By Michael Awood

October 19, 2023

Healthcare expenditure continues to rise, despite advances in medical training and technology. We’ve touched on this before, using an example from the US, where they have experienced these escalating costs. This was largely healthcare expenditure waste. Unfortunately, underperforming public services and poor health outcomes have been coupled with this. This, however, created the shift towards more efficient, cost-effective solutions. One such solution is the use of Artificial Intelligence (AI) in healthcare, and its role in reducing healthcare waste and cost.

AI has the potential to dramatically reduce inefficiencies in the healthcare system, leading to a more streamlined and cost-effective health ecosystem. This integration into healthcare is able to transform the approach to patient safety, hospital administration, drug development, and treatment decisions. AI is paving the way for rapid care management, enabling healthcare professionals to access real-time patient information at the touch of a button. This ability to quickly access and analyse patient data can significantly reduce casualties in emergency situations. The main outcome created is that of value

 

 The Economic Implications of AI in Healthcare

A start-up, backed by the University of Toronto, recently created a supercomputer algorithm to evaluate millions of potential Ebola treatments. This breakthrough creates value through cost and time reduction, and more importantly, it saves lives by improving existing treatments. With consumers (patients) increasingly using wearables, AI utilises this data for early detection of disease. This again reduces healthcare costs. In the referenced study it showed that AI significantly reduces healthcare costs compared to conventional methods.

The cost-saving due to AI used in treatment which has been found to be more effective than in diagnosis. AI not only enhances diagnostic accuracy but also minimizes inaccurate examinations, comforting patients.  In terms of time, AI-assisted tools require less time for diagnosis, resulting in cost savings. For instance, in the initial year, the time savings amount to 3.33 hours per day, and by the tenth year, the time saving reaches 15.17 hours per day. 

 

The Future of AI in Healthcare

AI must meet established quality requirements and importantly regulatory bodies must certify it. This will assist in the utilisation within healthcare, leading to full integration into existing systems. It would be important to conduct an economic analysis to compare the costs of AI-based diagnosis and treatment approaches with conventional approaches. These results show that it can significantly reduce healthcare costs compared to conventional methods.

AI possesses the potential to optimise the healthcare industry by reducing costs, improving efficiency, and enhancing patient care. However, to fully realise this potential, it is crucial to integrate AI into healthcare in a way that is economically viable and meets established quality standards.

 

Cover and in-text images taken from the article in the reference URL below

Reference url

Recent Posts

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

marstacimab hemophilia B
                

NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment Landscapes and Economic Implications

💡 Are we witnessing a paradigm shift in hemophilia treatment?

The recent recommendation from NICE for marstacimab as a novel therapy for severe hemophilia B is a game-changer. With its ability to provide effective prophylaxis while potentially lowering treatment costs, this could reshape patient care and health economics in this space.

Dive into the implications this has for patients and healthcare providers, and why marstacimab’s approval could be a pivotal moment for hemophilia management.

Explore the full article for deeper insights!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

HPV-related cancer trends
    

HPV-Related Cancer Trends in South Africa 2011-2021

🌍 Are we witnessing a rise in HPV-related cancer in South Africa?

A recent analysis of data from the South African National Cancer Registry highlights concerning trends: while cervical cancer rates are declining, there’s an alarming rise in non-cervical anogenital cancers. This underscores the urgent need for enhanced cancer prevention and access to efficient healthcare services in the country.

Dive into the findings and explore the implications for health systems and policies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.